[1] CHIAPPELLA A, CASTELLINO A, NICOLOSI M, et al. Diffuse large B-cell lymphoma in the elderly: standard treatment and new perspectives[J]. Expert Rev Hematol, 2017, 10(4): 289. doi: 10.1080/17474086.2017.1305264
[2] KUBUSCHOK B, HELD G, PFREUNDSCHUH M. Management of diffuse large B-cell lymphoma(DLBCL)[J]. Cancer Treat Res, 2015, 165: 271.
[3] CUI X, LI Q, HE Y. miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL[J]. Mol Cell Biochem, 2017, 424(1/2): 195.
[4] MCGUIRE A, BROWN JA, KERIN MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring[J]. Cancer Metastasis Rev, 2015, 34(1): 145. doi: 10.1007/s10555-015-9551-7
[5] 吴莹莹, 高波, 丁跃明, 等. miR-17-5p在肿瘤中作用的研究进展[J]. 中国肿瘤临床, 2016, 43(3): 130. doi: 10.3969/j.issn.1000-8179.2016.03.491
[6] JEFFERIES MT, COX AC, SHORNING BY, et al. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis[J]. J Pathol, 2017, 243(4): 442. doi: 10.1002/path.4977
[7] 任妮丽, 胡俊华, 吴方毅. miR-17-5p通过靶定PTEN调节结肠癌细胞增殖、侵袭和迁移能力的研究[J]. 解放军医药杂志, 2015(7): 56. doi: 10.3969/j.issn.2095-140X.2015.07.015
[8] HANS CP, WEISENBURGER DD, GREINER TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103(1): 275. doi: 10.1182/blood-2003-05-1545
[9] 佟丹江. 弥漫大B细胞淋巴瘤的流行病学分析[J]. 中国现代药物应用, 2016, 10(8): 46.
[10] COIFFIER B, SARKOZY C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do?[J]. Hematology Am Soc Hematol Educ Program, 2016(1): 366.
[11] ZHANG W, LIN J, WANG P, et al. miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells[J]. J Drug Target, 2017, 25(2): 125. doi: 10.1080/1061186X.2016.1207647
[12] CHEN C, LU Z, YANG J, et al. MiR-17-5p promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting p21[J]. Cancer Med, 2016, 5(12): 3489. doi: 10.1002/cam4.863
[13] LIU L, YANG J, ZHU X, et al. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer[J]. FEBSJ, 2016, 283(12): 2326.
[14] CONKRITE K, SUNDBY M, MUKAI S, et al. miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma[J]. Genes Dev, 2011, 25(16): 1734. doi: 10.1101/gad.17027411
[15] TAN W, LI Y, LIM SG, et al. miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(20): 5962. doi: 10.3748/wjg.v20.i20.5962
[16] KECHAGIOGLOU P, PAPI RM, PROVATOPOULOU X, et al. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression[J]. Anticancer Res, 2014, 34(3): 1387.
[17] NGEOW J, SESOCK K, ENG C. Breast cancer risk and clinical implications for germline PTEN mutation carriers[J]. Breast Cancer Res Treat, 2017, 165(1): 1. doi: 10.1007/s10549-015-3665-z
[18] DANKORT D, CURLEY DP, CARTLIDGE RA, et al. Braf(V600E)cooperates with Pten loss to induce metastatic melanoma[J]. Nat Genet, 2009, 41(5): 544. doi: 10.1038/ng.356
[19] TEKCHAM DS, GUPTA S, SHRIVASTAV BR, et al. Epigenetic downregulation of PTEN in gallbladder cancer[J]. J Gastrointest Cancer, 2017, 48(1): 110. doi: 10.1007/s12029-017-9919-8
[20] LI N, MIAO Y, SHAN Y, et al. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer[J]. Cell Death Dis, 2017, 18;8(5): e2796.
[21] 肖长艳, 郭子健, 曹磊, 等. Mir-106b表达与食管鳞状细胞癌的关系[J]. 南方医科大学学报, 2016, 36(12): 1667. doi: 10.3969/j.issn.1673-4254.2016.12.13
[22] FANG Y, XU C, FU Y. MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling[J]. J Biol Res(Thessalon), 2015, 22: 12.